Introduction
============

Gastric cancer is one of the most common cancers in Korea \[[@b1-crt-2014-018]\], and the fourth most common cancer worldwide \[[@b2-crt-2014-018]\]. Although the proportion of early gastric cancer has increased as a result of routine screening in Korea and Japan, gastric cancer is often diagnosed in the advanced stage. Complete resection with adequate margins is widely regarded as the standard of care. However, even after curative surgery, locoregional recurrence and distant metastasis are significant problems, and the survival outcome is usually unsatisfactory. The Intergroup 0116 (INT 0116) study \[[@b3-crt-2014-018]\] demonstrated a major survival advantage by the use of adjuvant chemoradiotherapy (CRT) following curative surgery. The results of this study have changed the standard of care favoring the use of both chemotherapy and radiation therapy (RT) in the postoperative setting. RT is now used more commonly in treatment of gastric cancer.

Treatment planning guidelines recommended by the INT 0116 study suggested that parallel opposed anteroposterior-posteroanterior (AP-PA) fields represent a practical arrangement for the majority of patients \[[@b4-crt-2014-018],[@b5-crt-2014-018]\]. With the wide availability of computerized treatment planning systems, the 3-dimensional (3D) plan has enabled more accurate delineation of high-risk target volumes, and usage of unconventional field arrangements for better dose distribution. However, computed tomography (CT)--based simulation was not mandatory in the past, and the majority of patients were treated based on the initial preoperative CT information, which did not reflect postoperative geometric changes in the internal organs. The internal organs were frequently relocated following surgery. An example of relocated kidneys delineated based on the preoperative CT ([Fig. 1A](#f1-crt-2014-018){ref-type="fig"}) and the postoperative simulation CT ([Fig. 1B](#f1-crt-2014-018){ref-type="fig"}) is shown in [Fig. 1](#f1-crt-2014-018){ref-type="fig"}. The actual location of the kidneys after surgery was shifted upwards, and a considerable portion of the left kidney could have been exposed to radiation if the treatment plan had been made based on the preoperative CT alone. Therefore, we hypothesize that use of the CT-based (3D) RT plan, via improved and optimized radiation dose delivery and normal tissue sparing, would lead to decreased treatment-related toxicity and improved survival outcomes.

The 2-dimensional (2D) plan based on the preoperative CT was used until July 2007, and the 3D simulation was adopted thereafter at Samsung Medical Center. The goals of our study were two-fold. First, we compared the dosimetric parameters of AP-PA beam arrangement between 3D simulation and the conventional fluoroscopic 2D-based simulation plan. A few clinical studies have reported on differences in the dosimetric parameters of 3D AP-PA versus 2D AP-PA plans. Second, we evaluated the clinical impact of 3D versus 2D simulation in terms of acute toxicity, recurrence, and survival, by performing a matched cohort study.

Materials and Methods
=====================

1. Patients' characteristics
----------------------------

Retrospective analyses were performed in 321 patients treated with adjuvant CRT following curative surgery and D2 dissection from 2006 to 2008 at Samsung Medical Center. Basic eligibility criteria for postoperative adjuvant treatment were similar to those used in the INT 0116 trial except for the inclusion of patients with positive resection margins after surgery \[[@b3-crt-2014-018]\]. RT with 2D plan, which was in concordance with the INT 0116 protocol, was applied in 121 patients from January 2006 to May 2007 (2D group). RT with a CT-based treatment plan was applied in 200 patients from June 2007 to September 2008 (3D group): AP-PA beams were used in 98 patients; and 3-beam arrangements were used in 102 patients. After exclusion of 102 patients treated with the CT-based 3-beam plan, 98 patients treated with the CT-based AP-PA plan were compared with their 2D counterparts. For the purpose of objective comparability, stages were matched, and 158 patients were eligible for the analysis: 98 patients in the 3D group; and 60 patients in the 2D group.

A list of the patients' demographic, treatment-related, and pathologic results is shown in [Table 1](#t1-crt-2014-018){ref-type="table"}. The median follow-up period was 24 months (range, 5 to 29 months) in the 3D group and 36 months (range, 5 to 51 months) in the 2D group. The median age was 53 years (range, 24 to 75 years), and male predominance was observed in both groups. The proportion of younger patients (≤ 50 years) was greater in the 3D group (36.7%) than in the 2D group (21.7%; p=0.041). No differences in the overall American Joint Committee on Cancer (AJCC) stage, T stage, and N stage were observed between the two groups. The 3D group included two patients with positive resection margins. A larger number of patients with close resection margins (less than 3 cm) was included in the 3D group than in the 2D group (47 and 23, respectively; p=0.024).

2. Chemotherapy
---------------

Two chemotherapy regimens were used during the current study period. The first regimen (IV fluorouracil and leucovorin \[FL\] regimen) consisted of intravenous fluorouracil (400 mg/m^2^/day) and intravenous leucovorin (20 mg/m^2^/day) for five consecutive days, starting at 3-7 weeks following surgery, followed by CRT beginning at four weeks after initiation of the first FL chemotherapy cycle. CRT consisted of a total radiation dose of 45 Gy over 5 weeks, with administration of intravenous fluorouracil (400 mg/m^2^/day) and leucovorin (20 mg/m^2^/day) on the first four and the last three days of RT. At 4 weeks following completion of CRT, two additional cycles of 5-day FL chemotherapy were administered at 4-week intervals.

The second chemotherapy regimen (oral capecitabine and cisplatin \[CP\] regimen) consisted of oral capecitabine (1,000 mg/m^2^, 2 times/day) for 14 consecutive days together with intravenous cisplatin (60 mg/m^2^/day) on the first day of each chemotherapy cycle spaced three weeks apart. After two cycles of CP chemotherapy, CRT, with the same RT dose schedule as in the FL regimen, was administered concurrently with oral capecitabine (825 mg/m^2^, 2 times/day) without intravenous cisplatin. At 3 weeks following completion of CRT, two additional cycles of CP chemotherapy were administered at 3-week intervals.

3. Radiation therapy
--------------------

### 1) 2D group

Preoperative CT information was used as a reference for the location of the normal organs before July 2007. RT simulation was performed in the supine position with the arms down. For identification of the anastomotic site and the duodenal stump, the suture line was identified on fluoroscopy with barium swallow. The superior margin of the field was set at the upper border of T11 vertebral body or the anastomotic site with at least a 2-cm margin. The inferior border was located at the junction of L2 and L3 vertebral bodies including the head of the pancreas. The right lateral margin was placed at the most lateral portion of the porta hepatis before the bifurcation of the right portal vein or at the duodenal stump or the head of the pancreas with a 1-cm margin. The left lateral border was placed at one vertebral body width from the left lateral border of the vertebrae ([Fig. 2](#f2-crt-2014-018){ref-type="fig"}). A total dose of 45 Gy over 5 weeks in daily fractions of 1.8 Gy was prescribed at the mid-depth at the isocenter by manual calculation without tissue heterogeneity correction.

### 2) 3D group

RT plan policy was changed from 2D to 3D in July 2007. CT simulation was performed in the supine position with the arms down using IV contrast media. Radiation was targeted to the anastomotic site, duodenal stump, and regional lymph nodes. The tumor bed was included in the radiation target volume only in the case of T4 lesion. The anastomotic site, duodenal stump, major vessels (celiac trunk, splenic vessels, superior mesenteric vessels), regional lymphatics around the major vessels, and normal parenchymal organs (liver, kidneys) were contoured on each CT slice for delineation of the clinical target volume (CTV) and the organs at risk (OAR). The remnant stomach was not included in the target volume, according to previous studies by Lim et al. \[[@b6-crt-2014-018]\] and Nam et al \[[@b7-crt-2014-018]\]. The anastomotic site was excluded from the radiation field if the gross resection margin was 5 cm or greater. If the resection margin was less than 3 cm, the anastomotic site was included in the radiation field. If the resection margin was between 3 cm and 5 cm, inclusion of the anastomotic site was individualized considering the possible radiation toxicity to the adjacent normal structures. The same principle was applied to the duodenal stump as well. The upper, lower, and lateral margins were similar to those of the previous 2D plan, but individually modified based on the internal anatomic relationships. The irradiated nodal regions were individually modified based on the primary tumor location and the surgical findings. The definition of the Japanese Gastric Cancer Association \[[@b8-crt-2014-018]\] was used to delineate the regional lymph node areas. Number 7, 8, 9, 11, 12, 13, 14, and 16 lymph nodes were usually included. The parallel opposing oblique beam arrangements usually within ±15 degree range were also used to reduce the radiation dose to the kidneys. A total dose of 45 Gy over 5 weeks in daily fractions of 1.8 Gy was prescribed usually at the isocenter or mid-point of the CTV ([Fig. 3](#f3-crt-2014-018){ref-type="fig"}).

### 3) RT plan comparison

The planning CT scans for each patient in the 3D group were retrieved for evaluation. For comparison of the dosimetric parameters between the 3D and 2D plans, second sets of radiation treatment plans were generated according to the same method used in the 2D group for each patient in the 3D group (virtual 2D plan of 3D group, V2D). The corresponding dose-volume histograms (DVHs) of V2D plans were recorded for the kidneys, liver, spinal cord, duodenum, pancreas, and bowel. The spinal cord, duodenum, and bowel are the typical serial organs, and the mean dose and the maximal point doses were recorded for comparison. The percentage of the kidney volume receiving more than 15 Gy (V15) and 20 Gy (V20), and the percentage of the liver volume receiving more than 30 Gy (V30) are widely used in the literature for evaluation of renal and hepatic toxicities and were used for the current comparison.

4. Clinical outcomes
--------------------

After completion of the planned adjuvant treatment course, regular follow-up was performed, including a physical examination, complete blood cell count (CBC), liver function test, chest X-ray, abdomino-pelvic CT, and gastrofiberscopy. Follow-up intervals were 3 months for the first year, 6 months for the next 2 years and yearly thereafter.

Local recurrence was defined as recurrence at any of the anastomotic sites, duodenal stump, remnant stomach, and tumor bed. Regional recurrence was defined as recurrence in the regional lymph nodes within the radiation field. Distant metastasis was defined as recurrence outside the radiation field, including remote lymph node, peritoneal seeding, and other solid organ metastasis. If two or more failure sites developed at the same time, they were counted separately.

Complications were scored using the Radiation Therapy Oncology Group (RTOG) toxicity criteria. The mean values of 3D and V2D were assessed using the paired t test. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan-Meier method. The survival duration was defined as the time from surgery to the events or the last follow-up without events. Chi-square test, Cochran Mantel-Haenszel test, and Wilcoxon rank-sum test were used for comparison of differences in the prognostic factors, patterns of recurrence, and complication between the groups. Statistical significance was set at α=0.05. A p-value was based on two-sided tests.

Results
=======

1. Dosimetric impact
--------------------

Two different RT plans derived from the same patient in the 3D group (3D vs. V2D) were compared. The median field width and length in the 3D group and V2D group was 10.0 cm (range, 8.0 to 15.0 cm) and 12.5 cm (range, 9.0 to 17.0 cm), and 13.0 cm (range, 11.0 to 15.0 cm) and 14.8 cm (range, 12.0 to 17.0 cm), respectively (p \< 0.05), as shown in [Table 2](#t2-crt-2014-018){ref-type="table"}. A summary of the differences in DVHs between the two groups is shown in [Table 3](#t3-crt-2014-018){ref-type="table"}. All dosimetric parameters of normal tissues were lower in the 3D group, without exception.

2. Clinical outcomes
--------------------

The OS rates were 95.7%, 89.5%, 82.2%, and 68.9% at 1, 2, 3, and 4 years, respectively. The DFS rates were 88.3%, 75.2%, 71.5%, 64.3% at 1, 2, 3, and 4 years, respectively. No difference in OS and DFS was observed between groups. No statistically significant differences in local, regional, and distant recurrence-free survival were observed between groups.

A list of patients with local or regional recurrences is shown in [Table 4](#t4-crt-2014-018){ref-type="table"}. Out of eight patients with local failure, six showed failure in the anastomotic site and two showed failure in the duodenal stump. Regional recurrence was observed in eight patients, four patients of the 3D group and four patients of the 2D group, respectively. All local or regional failures were either in-field or combined in- and out-field recurrences.

The prognostic factors for DFS and OS were evaluated by variables including age (≤ 50 years vs. \> 50 years), sex, Eastern Cooperative Oncology Group (ECOG), T, N, stage, pathology, tumor grade, status of the resection margin, type of surgery, chemotherapy, and RT plan. In univariate analysis, ECOG 1 and 2 were poor prognostic factors compared to ECOG 0, advanced T, N and AJCC stage, positive or close resection margin, and type of surgery (subtotal gastrectomy with Billroth II reconstruction and total gastrectomy was worse than subtotal gastrectomy with Billroth I reconstruction) for DFS, distant recurrence-free survival, and OS, and close resection margin for regional recurrence-free survival. In multivariate analysis, ECOG, advanced T and N, and status of the resection margin were meaningful for OS.

The acute toxicity profiles of patients treated with FL regimen and those treated with CP regimen were analyzed separately. No difference was observed in both groups during and one month post-RT regardless of the chemotherapy regimen used, as shown in [Table 5](#t5-crt-2014-018){ref-type="table"}, whereas the between-group difference in the incidence of acute toxicity during RT with FL regimen was marginal (p=0.054).

Major complications, including grade 4 bowel toxicity were observed in two patients of the 2D group. Small bowel resection and anastomosis was performed in one patient with bowel perforation at six months post-adjuvant CRT and in the other patient with adhesive bowel obstruction at 14 months post-treatment.

Serial changes in CBC and blood chemistry of all patients were assessed at five time points before, during, and after RT: preoperative (baseline); postoperative (before the first chemotherapy); pre-RT; during RT; and after RT (at 3-4 weeks after completion of RT, just before initiation of the next chemotherapy cycle). No statistically significant differences in CBC and blood chemistry tests were observed between the two groups, as shown in [Fig. 4](#f4-crt-2014-018){ref-type="fig"}.

Discussion
==========

This is the first study to quantify the dosimetric and clinical influences of the 3D plan with CT-based simulation in postoperative CRT for gastric cancer in terms of AP-PA field arrangement. The term first was used after conducting electronic searches on PubMed using the following keywords: *stomach cancer, postoperative radiation therapy, CT simulation, AP-PA*, and *clinical outcomes*. Theoretically, 3D-CRT enables more conformal dose delivery and normal tissue sparing than classic 2D RT. Several studies concerning radiation field arrangements in postoperative CRT for gastric cancer from the dosimetric aspects have been reported. For example, an Australian group suggested the 'split-field' technique, instead of the AP-PA plan, by dividing the planning target volume into two abutting sections, with each section treated using a separate, optimized field arrangement \[[@b9-crt-2014-018]\]. They reported lower mean doses to the right kidney (18 Gy vs. 35 Gy in 1/3 kidney, 6 Gy vs. 4 Gy in 2/3 kidney), the left kidney (18 Gy vs. 40 Gy in 1/3 kidney, 5 Gy vs. 5 Gy in 2/3 kidney), and the spinal cord (17 Gy vs. 45 Gy), and a higher dose to the liver (mean, 31 Gy vs. 10 Gy in 1/3 liver) in 15 studied patients. However, the problems of match-line, such as generation of cold or hot area, were unavoidable despite using a single isocenter technique. Another report by a group in Israel compared a non-coplanar four-field arrangement with the AP-PA plan and the four-field "box" technique in 19 patients \[[@b10-crt-2014-018]\]. According to the results, the doses to the spinal cord and both kidneys were significantly lowered by use of the non-coplanar four-field technique. Intensity-modulated RT (by either step-and-shoot or tomotherapy) is another treatment option under investigation, with more sparing of dose to the kidney and cord. However, it appears to offer only limited advantages when compared with sophisticated 3D conformal RT planning \[[@b11-crt-2014-018]\]. All of these studies were plan comparison studies using multiple beam arrangements with AP-PA plans without clinical results, which are different from the current study comparing AP-PA 2-beam arrangements contingent upon CT simulation and analyzing relevant clinical results in a larger number of patients. The gastric cancer consensus report \[[@b4-crt-2014-018]\] stated that "parallel opposed AP-PA fields are considered the most practical arrangement for the overwhelming majority of postoperative adjuvant radiotherapy cases." In addition, the current National Comprehensive Cancer Network (NCCN) guidelines strongly recommend the use of CT simulation and 3D treatment plan. However, the CT-based simulation was not mandatory in the past and the majority of patients were treated based on the initial preoperative CT information, which did not reflect the postoperative anatomic changes. The gastric surgical adjuvant RT consensus report \[[@b4-crt-2014-018]\] recommended obtainment of three sets of simulation films for the traditional 2D treatment plan: the first set for identification of surgical clips and staple lines; the second set following administration of intravenous contrast for identification of the location of the kidneys; and the final set following barium swallow for identification of the anastomotic site, as well as the gastric stump. Before the CT era, the second set was not routinely obtained in practice following administration of intravenous contrast, and the first and third sets were usually used for the 2D simulation. The primary sites of the tumor, the major vasculature including the celiac axis, superior and inferior mesenteric arteries, porta hepatis, splenic artery, and both kidneys were identified based on preoperative CT images, without considering the probable postoperative position shifts. Only on rare occasions, when CT scan was performed postoperatively because of surgical problems, such as abdominal pain with fever, sustained ileus, suspicious abscess formation, etc., the postoperative CT scan could be used as the reference for the target delineation.

It is usually recommended that the doses to the surrounding organs should be kept as low as possible in order to reduce treatment-related side effects. In this study, for the purpose of comparing the dosimetric parameters between plans with or without CT-based simulation, second alternative RT plans, which followed the conventional 2D plan method with anatomic reference using the preoperative CT, were generated in the same patients. As expected, the CT-based simulation provided better DVH profiles than the traditional virtual simulation. Accurate visualization of the kidneys could be helpful in providing more appropriate renal shielding. All dosimetric parameters of the normal tissues were lower in patients of the 3D group, without exception. The kidneys, most notably, are sensitive to low dose radiation. Emami et al. \[[@b12-crt-2014-018]\] reported that the tolerance doses associated with a 5% risk of renal dysfunction at five years were 23 Gy after single, whole kidney irradiation and 20 Gy if both kidneys were irradiated. In addition, it is known that development of radiation-induced nephropathy could occur even at doses lower than the tolerance limit. Although there are reports of development of impaired renal function in children at 12 to 14 Gy \[[@b13-crt-2014-018]\], the threshold dose for renal damage in adults with normal baseline renal function is approximately 15 Gy with conventional fractionation. Renal damage may not manifest for years following RT, therefore, long-term follow-up is important. In one long-term study, the latent period was \> 10 years in nearly half of the patients \[[@b14-crt-2014-018]\]. Therefore, the renal dose should be kept as low as possible through careful treatment planning, and CT simulation appears mandatory to achievement of this goal. In the current study, the mean dose to the left kidney was 767.4 cGy versus 1,734.2 cGy and that of the right kidney was 656.0 cGy versus 965.0 cGy for the 3D and V2D group favoring CT simulation, respectively (p \< 0.001 for the left kidney, and p=0.004 for the right kidney). The mean dose to the spinal cord also favored the 3D group. Emami et al. \[[@b12-crt-2014-018]\] suggested 45 Gy as the cord tolerance dose. However, the maximal cord dose was 4,874.9 cGy in the V2D group, which was significantly higher than 4,737.5 cGy in the 3D group (p \< 0.001). The mean dose to the liver was subclinical in all patients.

However, these improved dose profiles were not associated with better clinical outcomes of toxicity profiles, survival, and relapse patterns. There were no between-group differences in clinical features (all p \> 0.05), whereas the difference in the incidence of acute toxicity during RT with FL regimen was marginal with a p-value of 0.054. The plan comparison was performed between the 3D group and the V2D group, a virtual 2D plan of the 3D group, not between the 3D group and the 2D group. In this respect, it should be considered that the dosimetric results of the V2D group may not reflect the actual clinical features of the 2D group as in the 3D group.

In summary, the 3D plan enabled precise delineation of the target volume and OAR by visualization of geometric changes in the internal organs after surgery. The DVH of normal tissues in the 3D plan was superior to that of the V2D plan; however, similar clinical features were observed between the 3D group and the 2D group.

Conclusion
==========

The dosimetric parameters of normal tissues in the 3D AP-PA plan were lower than those of the V2D AP-PA plan, without exception, however, the clinical features, including acute toxicity, recurrence, and survival were similar between the 3D group and the 2D group. Our findings could facilitate understanding of the merits and demerits of CT-based AP-PA planning over 2D planning in postoperative treatment of patients with advanced gastric cancer.
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![The anatomic relationship between the location of the kidneys and the radiation treatment field. The portion of the left kidney included in the radiation therapy (RT) field is highlighted in yellow color based on the preoperative computed tomography (CT) (A) and on the simulation CT (B) in the same patient. The actual location of the kidneys after surgery was shifted upward and a considerable portion of the left kidney was exposed to radiation during the actual treatment if the treatment plan had been made based on the preoperative CT. The portion of the right kidney included in the RT field is highlighted in green and no significant difference in terms of irradiated kidney volume was observed between the preoperative CT (A) and the simulation CT (B) in this patient.](crt-2014-018f1){#f1-crt-2014-018}

![Radiation field of the 2D group.](crt-2014-018f2){#f2-crt-2014-018}

![Radiation field of the 3D group. (A) Axial plane with isodose curves and 2-beam arrangement in group 2A is shown. The white arrows represents 100% isodose line in red color. (B) Beam view of the anterior beam of the 3D group is shown here.](crt-2014-018f3){#f3-crt-2014-018}

![Serial changes of complete blood cell count and blood chemistry of all patients at five time points before, during, and after radiation therapy (RT): preoperative (baseline); postoperative (before the first cycle of chemotherapy); pre-RT (right before the start of RT); during RT; and after RT (at 3-4 weeks after completion of RT and before the start of next chemotherapy). (A) Hemoglobin. (B) White blood cell count. (C) Absolute neutrophil count. (D) Aspartate aminotransferase. (E) Alanine aminotransferase. (F) Blood urea nitrogen. (G) Creatinine. Solid squares, open squares, and bars indicate 3D group, 2D group, and standard error, respectively.](crt-2014-018f4){#f4-crt-2014-018}

###### 

Patients' characteristics

  Variable                                 Total (n=158)   3D group (n=98)   2D group (n=60)                                         p-value
  ---------------------------------------- --------------- ----------------- ------------------------------------------------------- ---------
  Age (yr)                                                                                                                           
   ≤ 50                                    49 (31.0)       36 (36.7)         13 (21.7)                                               0.041
   \> 50                                   109 (69.0)      62 (63.3)         47 (78.3)                                               
  Gender                                                                                                                             
   Male                                    114 (72.2)      76 (77.5)         38 (63.3)                                               0.026
   Female                                  44 (27.8)       22 (22.5)         22 (36.7)                                               
  ECOG PS                                                                                                                            
   0                                       68 (43.0)       46 (47.0)         22 (36.7)                                               0.129
   1                                       89 (56.3)       52 (53.0)         37 (61.7)                                               
   2                                       1 (0.70)        0                 1 (1.6)                                                 
  Stage                                                                                                                              
   IB                                      32 (20.3)       20 (20.4)         12 (20.0)                                               0.993
   II                                      53 (33.5)       33 (33.7)         20 (33.3)                                               
   IIIA                                    25 (15.8)       15 (15.3)         10 (16.7)                                               
   IIIB                                    16 (10.1)       10 (10.2)         6 (10.0)                                                
   IV                                      32 (20.3)       20 (20.4)         12 (20.0)                                               
  T stage                                                                                                                            
   1                                       22 (13.9)       12 (12.2)         10 (16.7)                                               0.711
   2                                       82 (51.9)       54 (55.1)         28 (46.6)                                               
   3                                       47 (29.8)       28 (28.6)         19 (31.7)                                               
   4                                       7 (4.4)         4 (4.1)           3 (5.0)                                                 
  N stage                                                                                                                            
   0                                       22 (13.9)       16 (16.3)         6 (10.0)                                                0.664
   1                                       79 (50.0)       46 (46.9)         33 (55.0)                                               
   2                                       28 (17.7)       18 (18.4)         10 (16.7)                                               
   3                                       29 (18.4)       18 (18.4)         11 (18.3)                                               
  Type of surgery                                                                                                                    
   Subtotal gastrectomy, billoth type I    72 (45.8)       46 (46.9)         26 (43.3)                                               0.847
   Subtotal gastrectomy, billoth type II   20 (11.5)       12 (12.3)         8 (13.3)                                                
   Total gastrectomy                       65 (41.9)       40 (40.8)         25 (41.7)                                               
   Others                                  1 (0.8)         0                 1[^a)^](#tfn2-crt-2014-018){ref-type="table-fn"}(1.7)   
  Histology                                                                                                                          
   Adenocarcinoma                          110 (69.6)      65 (66.4)         45 (75.0)                                               0.442
   Signet ring cell                        45 (28.5)       32 (32.6)         13 (21.7)                                               
   Undifferentiated                        3 (1.9)         1 (1.0)           2 (3.3)                                                 
  Resection margin (cm)                                                                                                              
   Negative adequate (\> 3)                86 (54.4)       49 (50.0)         37 (61.7)                                               0.024
   Negative close (≤ 3)                    70 (44.3)       47 (48.0)         23 (38.3)                                               
   Positive                                2 (1.3)         2 (2.0)           0                                                       
  Chemotherapy                                                                                                                       
   IV fluorouracil and leucovorin          86 (54.4)       47 (48.0)         39 (65.0)                                               0.048
   Oral capecitabine and cisplatin         72 (45.6)       51 (52.0)         21 (35.0)                                               

3D, 3-dimensional; 2D, 2-dimensional; ECOG PS, Eastern Cooperative Oncology Group performance score.

Ivor-Lewis operation.

###### 

Field size difference of 3D group and V2D group

  Size              3D[^a)^](#tfn3-crt-2014-018){ref-type="table-fn"}   V2D[^b)^](#tfn4-crt-2014-018){ref-type="table-fn"}   p-value
  ----------------- --------------------------------------------------- ---------------------------------------------------- ----------
  Width (cm)                                                                                                                 
   Mean±SD          10.1±1.3                                            13.2±0.8                                             \< 0.001
   Median (range)   10.0 (8.0-15.0)                                     13.0 (11.0-15.0)                                     
  Length (cm)                                                                                                                
   Mean±SD          12.5±1.8                                            14.7±1.0                                             \< 0.001
   Median (range)   12.5 (9.0-17.0)                                     14.8 (12.0-17.0)                                     

Three-dimensional (3D) plan of the 3D group,

Virtual 2-dimensional (2D) plan of the 3D group.

###### 

Dosimetric comparison of 3D group and V2D group

  Variable                         3D[^a)^](#tfn5-crt-2014-018){ref-type="table-fn"}   V2D[^b)^](#tfn6-crt-2014-018){ref-type="table-fn"}   p-value
  -------------------------------- --------------------------------------------------- ---------------------------------------------------- ----------
  Maximal point dose, mean (cGy)   4,949.2                                             5,075.6                                              0.112
  Left kidney                                                                                                                               
   Mean dose (cGy)                 767.4                                               1,734.2                                              \< 0.001
   Maximal point dose (cGy)        4,290.9                                             4,773.0                                              \< 0.001
   V15 (mL)                        77.0                                                116.7                                                0.584
   V20 (mL)                        24.9                                                60.0                                                 \< 0.001
  Right kidney                                                                                                                              
   Mean dose (cGy)                 656.0                                               965.0                                                0.004
   Maximal point dose (cGy)        4,398.3                                             4,649.2                                              \< 0.001
   V15 (mL)                        21.2                                                94.3                                                 0.215
   V20 (mL)                        16.7                                                89.6                                                 0.174
  Liver                                                                                                                                     
   Mean dose (cGy)                 878.1                                               1,435.3                                              \< 0.001
   Maximal point dose (cGy)        4,726                                               4,810.5                                              0.108
   V30 (mL)                        191.5                                               342.5                                                \< 0.001
  Cord (cGy)                                                                                                                                
   Mean dose                       2,264.9                                             2,683.4                                              0.001
   Maximal point dose              4,737.5                                             4,874.9                                              \< 0.001
  Bowel (cGy)                                                                                                                               
   Mean dose                       924.5                                               1,488.5                                              \< 0.001
   Maximal point dose              4,802.2                                             4,852.8                                              0.684
  Duodenum (cGy)                                                                                                                            
   Mean dose                       2,829.9                                             3,235.5                                              0.212
   Maximal point dose              4,537.2                                             4,635.9                                              0.050
  Pancreas (cGy)                                                                                                                            
   Mean dose                       3,428.8                                             4,063.5                                              \< 0.001
   Maximal point dose              4,672.8                                             4,690.3                                              0.379

Three-dimensional (3D) plan of the 3D group,

Virtual 2-dimensional (2D) plan of the 3D group.

###### 

Patients with local and regional recurrences

  No   Age (yr)/Gender   Group   Stage   Failure                                                        Relationship with RT field   DFS (mo)   OS (mo)   Survival status
  ---- ----------------- ------- ------- -------------------------------------------------------------- ---------------------------- ---------- --------- ------------------------------------------------------
  1    68/F              3D      II      A-site (Bx proven) + regional LNs (9, 13)                      In field                     5          9         Alive[^a)^](#tfn8-crt-2014-018){ref-type="table-fn"}
  2    51/M              3D      II      A-site (Bx proven) + regional LNs (9, 13) A-site (Bx proven)   In/out field                 19         26        Alive[^a)^](#tfn8-crt-2014-018){ref-type="table-fn"}
  3    72/M              3D      IV      Regional LNs (9, 13)                                           In field                     11         32        Alive[^a)^](#tfn8-crt-2014-018){ref-type="table-fn"}
  4    75/M              3D      II      Regional LNs (13)                                              In field                     11         23        Alive[^a)^](#tfn8-crt-2014-018){ref-type="table-fn"}
  5    72/M              2D      IIIB    A-site (Bx proven)                                             In field                     11         12        Dead
  6    55/M              2D      II      Regional LNs (9)                                               In/out field                 28         37        Dead
  7    46/F              2D      IIIB    Regional LNs (13) + peritoneal seeding                         In/out field                 35         46        Alive[^a)^](#tfn8-crt-2014-018){ref-type="table-fn"}
  8    58/F              2D      IV      Regional LNs (16)                                              In field                     18         41        Alive[^a)^](#tfn8-crt-2014-018){ref-type="table-fn"}
  9    74/F              2D      IB      Regional LNs (16)                                              In field                     19         23        Dead
  10   63/M              2D      II      Duodenal stump + peritoneal seeding                            In/out field                 13         29        Dead
  11   45/M              2D      IV      A-site (Bx proven)                                             In field                     22         32        Alive[^a)^](#tfn8-crt-2014-018){ref-type="table-fn"}

RT, radiation therapy; DFS, disease-free survival; OS, overall survival; A-site, anastomosis site; Bx, biopsy; LN, lymph node.

Alive with disease.

###### 

Acute GI toxicities by treatment group

  Maximal GI toxicity   FL regimen   CP regimen                                   
  --------------------- ------------ ------------ ------- ----------- ----------- -------
  During RT                                       0.054                           0.927
   Grade 0              12 (25.5)    6 (15.4)             16 (31.4)   7 (33.3)    
   Grade 1              24 (51.1)    18 (46.1)            28 (54.9)   10 (47.6)   
   Grade 2              9 (19.1)     11 (28.2)            5 (9.8)     3 (14.3)    
   Grade 3 or higher    2 (4.3)      4 (10.3)             2 (3.9)     1 (4.8)     
  1-Month post-RT                                 0.493                           0.476
   Grade 0              17 (36.2)    13 (33.3)            21 (41.2)   8 (38.1)    
   Grade 1              26 (55.3)    20 (51.3)            27 (52.9)   11 (52.4)   
   Grade 2              3 (6.4)      4 (10.3)             3 (5.9)     1 (4.8)     
   Grade 3 or higher    1 (2.1)      2 (5.1)              \-          1 (4.8)     

GI, gastrointestinal; FL, intravenous fluorouracil and leucovorin; CP, oral capecitabine and cisplatin; 2D, 2-dimensional; 3D, 3-dimensional; RT, radiation therapy.
